Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission
- PMID: 24447607
- PMCID: PMC3901753
- DOI: 10.1186/1479-5876-12-18
Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission
Abstract
Background: Bone marrow (BM) aspiration is largely used for relapse assessment in acute myeloid leukemia (AML). It remains unclear what roles that BM trephine biopsy plays on relapse assessment.
Methods: Bone marrow (BM) sections during complete remission (CR) from 60 acute myeloid leukemia (AML) patients were retrospectively analyzed. Computer image processing technology was performed for detection of the distance between precursors and endosteum, and density of precursors was also calculated under light microscopic image. Immunohistochemistry was used to identify the immunophenotype of clustered precursors.
Results: Except for single and double precursors, there existed clustered precursors of 3-5 cells during CR. Here, we demonstrated that clustered precursors, but not single and double precursors, were useful in risk factor of relapse. Area under the receiving operator curve (ROC) was of 0.007 (CI 95%, from 0.572 to 0.851). Using a standard cut-off value of >4.0/mm² for cluster density, early relapse was detected with a sensitivity of 51.5% and a specificity of 85.7%.Multivariate Cox regression analysis revealed that clustered precursor is an independent risk factor for early relapse (Adjusted HR: 0.325, 95% CI: 0.156-0.679, p = 0.003).
Conclusions: Cumulatively, clustered precursors in BM sections during CR may serve as an independent risk factor of early relapse and poor outcome for AML patients in cluster density > 4.0/mm² in sections. Early aggressive interventions are needed to prevent hematologic relapse.
Figures
References
-
- Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ. International BFM Study Group on Paediatric AML. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148:768–776. doi: 10.1111/j.1365-2141.2009.08011.x. - DOI - PubMed
-
- Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ, Creutzig U. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010;24:1422–1428. doi: 10.1038/leu.2010.127. - DOI - PubMed
-
- Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica. 2010;95:1857–1864. doi: 10.3324/haematol.2010.027516. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
